Gyre Therapeutics, Inc.
GYRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001124105
No open-market purchases or sales by Gyre Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $57.1M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Gyre Therapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 66 | 51 | −15 |
| Shares | 18.4M | 15.0M | −3.34M (−18.1%) |
| Value | $75.7M | $13.7M | −$61.9M (−81.8%) |
New holders (12)
Institutions that held Gyre Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Assenagon Asset Management S.A. | 512,643 | $469.0K | 0.00% |
| Acadian Asset Management LLC | 232,400 | $211.0K | 0.00% |
| Gyon Technologies Capital Management, LP | 156,550 | $143.0K | 0.03% |
| D. E. Shaw & Co., Inc. | 140,186 | $128.0K | 0.00% |
| Kynam Capital Management, LP | 110,991 | $101.0K | 0.05% |
| Marshall Wace, LLP | 67,605 | $61.0K | 0.00% |
| Susquehanna International Group, LLP | 40,928 | $38.0K | 0.00% |
| Jane Street Group, LLC | 17,379 | $16.0K | 0.00% |
| Engineers Gate Manager LP | 16,076 | $15.0K | 0.00% |
| Geneos Wealth Management Inc. | 8,214 | $7.00K | 0.00% |
| UBS Group AG | 5,205 | $5.00K | 0.00% |
| Simplex Trading, LLC | 2,294 | $2.00K | 0.00% |
Sold out (27)
Institutions that held Gyre Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.